Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: secukinumab
Drug: Placebo

First Posted Date: 2019-11-29

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 275

Registration Number: NCT04181762

Locations: 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸
Kaiser Permanente Fontana, Fontana, California, United States
🇺🇸
University of California LA, Los Angeles, California, United States

and more 6 locations

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Phase 3

Active, not recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: secukinumab

First Posted Date: 2019-11-27

Last Posted Date: 2024-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 704

Registration Number: NCT04179175

Locations: 🇺🇸
Northwest Arkansas Center, Rogers, Arkansas, United States
🇺🇸
MedDerm Associates, San Diego, California, United States
🇺🇸
Southern California Skin and Laser, Whittier, California, United States

and more 27 locations

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting

Conditions: Spinal Muscular Atrophy (SMA)

Interventions: Other: Prospective observational registry
Drug: Zolgensma

First Posted Date: 2019-11-22

Last Posted Date: 2024-11-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT04174157

Locations: 🇬🇷
Penteli Children's Hospital, Penteli, Attikis, Greece
🇬🇷
St. Sophia Children's Hospital, Thessaloniki, Greece
🇯🇵
Nikko Memorial Hospital, Hokkaido, Japan

and more 96 locations

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Phase 2

Completed

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: LCZ696
Drug: Placebo

First Posted Date: 2019-11-15

Last Posted Date: 2024-08-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT04164732

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Placebo
Drug: Secukinumab

First Posted Date: 2019-11-07

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 527

Registration Number: NCT04156620

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Phase 2

Withdrawn

Conditions: B-cell Acute Lymphoblastic Leukemia

Interventions: Biological: Tisagenlecleucel

First Posted Date: 2019-11-07

Last Posted Date: 2023-03-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04156659

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

Phase 2

Terminated

Conditions: Idiopathic Membranous Nephropathy

Interventions: Drug: LNP023
Drug: Rituximab

First Posted Date: 2019-11-06

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT04154787

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: MBG453
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2019-11-04

Last Posted Date: 2024-08-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT04150029

Locations: 🇺🇸
Duke Univ Medical Center ., Durham, North Carolina, United States
🇺🇸
Chattanooga Onc And Hem Assoc PC Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States
🇺🇸
Huntsman Cancer Institute Univ of Utah ., Salt Lake City, Utah, United States

and more 10 locations

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Non-alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions: Drug: LYS006
Drug: Tropifexor

First Posted Date: 2019-11-01

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT04147195

Locations: 🇩🇪
Novartis Investigative Site, Essen, Nordrhine Westphalia, Germany

Heart Failure IDentification in a High Risk Cardiovascular OutpatiEnt Population (HIDE)

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Diagnostic Test: NYHA assessment
Procedure: Serum NT-proBNP concentration
Diagnostic Test: Transthoracic Ecocardiogram

First Posted Date: 2019-10-30

Last Posted Date: 2022-03-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 317

Registration Number: NCT04143919

Locations: 🇬🇹
Novartis Investigative Site, Guatemala city, Guatemala

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy